Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Depreciation & Amortization - Total: 2018-2024

Historic Depreciation & Amortization - Total for Akebia Therapeutics (AKBA) over the last 7 years, with Dec 2024 value amounting to $1.5 million.

  • Akebia Therapeutics' Depreciation & Amortization - Total fell 12.40% to $318,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 15.65%. This contributed to the annual value of $1.5 million for FY2024, which is 7.76% down from last year.
  • As of FY2024, Akebia Therapeutics' Depreciation & Amortization - Total stood at $1.5 million, which was down 7.76% from $1.6 million recorded in FY2023.
  • Akebia Therapeutics' 5-year Depreciation & Amortization - Total high stood at $2.1 million for FY2020, and its period low was $1.5 million during FY2024.
  • Moreover, its 3-year median value for Depreciation & Amortization - Total was $1.6 million (2023), whereas its average is $1.6 million.
  • Data for Akebia Therapeutics' Depreciation & Amortization - Total shows a maximum YoY declined of 12.95% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Akebia Therapeutics' Depreciation & Amortization - Total stood at $2.1 million in 2020, then dropped by 9.52% to $1.9 million in 2021, then declined by 12.95% to $1.7 million in 2022, then dropped by 4.17% to $1.6 million in 2023, then decreased by 7.76% to $1.5 million in 2024.